Auxotrophic recombinant Mycobacterium bovis BCG overexpressing Ag85B enhances cytotoxicity on superficial bladder cancer cells in vitro
- 30 September 2012
- journal article
- biotechnological products-and-process-engineering
- Published by Springer Nature in Applied Microbiology and Biotechnology
- Vol. 97 (4) , 1543-1552
Abstract
BCG therapy remains at the forefront of immunotherapy for treating patients with superficial bladder cancer. The high incidence of local side effects and the presence of non-responder diseases have led to efforts to improve the therapy. Hence, we proposed that an auxotrophic recombinant BCG strain overexpressing Ag85B (BCG ∆leuD/Ag85B), could enhance the cytotoxicity to the human bladder carcinoma cell line 5637. The rBCG was generated using an expression plasmid encoding the mycobacterial antigen Ag85B to transform a BCG ∆leuD strain. The inhibitory effect of BCG ∆leuD/Ag85B on 5637 cells was determined by the MTT method, morphology observation and a LIVE/DEAD assay. Gene expression profiles for apoptotic, cell cycle-related and oxidative stress-related genes were investigated by qRT-PCR. Bax, bcl-2 and p53 induction by BCG ∆leuD/Ag85B treatment was evaluated by Western blotting. BCG ∆leuD/Ag85B revealed a superior cytotoxicity effect compared to the control strains used in this study. The results showed that the expression level of pro-apoptotic and cell cycle-related genes increased after BCG ∆leuD/Ag85B treatment, whereas the mRNA levels of anti-apoptotic genes decreased. Interestingly, BCG ∆leuD/Ag85B also increased the mRNA level of antioxidant enzymes in the bladder cancer cell line. Bax and p53 proteins levels increased following treatment. In conclusion, these results suggest that treatment with BCG ∆leuD/Ag85B enhances cytotoxicity for superficial bladder cancer cells in vitro. Therefore, rBCG therapy may have potential benefits in the treatment of bladder cancer.Keywords
This publication has 54 references indexed in Scilit:
- Antitumor effects of human interferon-alpha 2b secreted by recombinant bacillus Calmette-Guérin vaccine on bladder cancer cellsJournal of Zhejiang University-SCIENCE B, 2012
- UVA-induced cyototoxicity and DNA damaging potential of benz (e) acephenanthryleneToxicology Letters, 2010
- The therapeutic potential of recombinant BCG expressing the antigen S1PT in the intravesical treatment of bladder cancerUrologic Oncology: Seminars and Original Investigations, 2010
- Identification, tissue distribution and evaluation of brain neuropeptide Y gene expression in the Brazilian flounder Paralichthys orbignyanusJournal of Biosciences, 2010
- Improvement of bladder cancer immunotherapy by creating a recombinant Bacille Calmette-Gu’erin which secrets p53 proteinMedical Hypotheses, 2009
- Comparative Anticancer and Antioxidant Activities of Different Ingredients ofGinkgo bilobaExtract (EGb 761)Planta Medica, 2009
- Auxotrophic complementation as a selectable marker for stable expression of foreign antigens in Mycobacterium bovis BCGTuberculosis, 2007
- Instruction of naive CD4+ T‐cell fate to T‐bet expression and T helper 1 development: roles of T‐cell receptor‐mediated signalsImmunology, 2007
- The Treated Natural History of High Risk Superficial Bladder Cancer: 15-year OutcomeJournal of Urology, 1997
- Apoptosis Meets Signal Transduction: Elimination of a BAD InfluenceCell, 1996